Skip to content


Soliris (eculizumab) is an antibody pharmaceutical. Eculizumab was first approved as Soliris on 2007-03-16. It is used to treat atypical hemolytic uremic syndrome and paroxysmal hemoglobinuria in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. The pharmaceutical is active against complement C5.
Trade Name Soliris
Common Name Eculizumab
Indication atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now